Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc. has demonstrated significant promise in its drug development pipeline, particularly with AN2-502998, which achieved 100% survival in non-human primate models for Chagas disease, surpassing previously developed agents from established pharmaceutical companies. The recognition of unmet medical needs in diseases such as Chagas and melioidosis further enhances the strategic importance of AN2's therapeutic candidates. Although additional safety data from human trials is required for comprehensive valuation, the company's innovative boron-based compounds and positive preclinical results point toward a favorable long-term outlook for AN2 Therapeutics's stock.

Bears say

AN2 Therapeutics Inc has a persistent history of financial losses and lacks a proven track record of profitability, raising concerns about its long-term viability. The company's ability to successfully partner for favorable terms is uncertain, which could jeopardize the success of any potential commercial launch. Additionally, the risks associated with the efficacy and safety of its drug candidates in clinical development could hinder approval and commercialization efforts, further complicating its financial outlook.

ANTX has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 2 analysts, ANTX has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.